Sign In
Buy OGN
$13.40
+0.0200 (+0.149%)
At Close: Jun 03, 2026
Orogen Royalties Announces Non-Brokered Private Placement of up to $10 Million
07:30am, Thursday, 12'th Mar 2026
VANCOUVER, BC / ACCESS Newswire / March 12, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce it intends to raise up to $10,000,000 by way of a no
STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (P
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis
02:01pm, Monday, 02'nd Mar 2026
Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.
Orogen Royalties Creates a Royalty on the Ecru Gold Project in Nevada, USA
08:30am, Friday, 27'th Feb 2026
VANCOUVER, BC / ACCESS Newswire / February 27, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains.
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
07:30am, Monday, 23'rd Feb 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty
04:56am, Sunday, 22'nd Feb 2026
Organon reported a disappointing Q4, with revenue down 5% YoY and significant weakness in women's health. Shares are heavily oversold, but I maintain a Hold rating due to strategic uncertainty and lac
Fiserv Inc: A Significant Move in Jeff Auxier's Portfolio
06:09pm, Tuesday, 17'th Feb 2026
Exploring the Strategic Investment Decisions of a Renowned Value Investor Jeff Auxier (Trades, Portfolio) recently submitted the 13F filing for the fourth quar
Orogen Royalties Announces Annual Equity Compensation Grant
07:00pm, Friday, 13'th Feb 2026
VANCOUVER, BC / ACCESS Newswire / February 13, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") announces that, as part of the Company's annual share-based compensation
Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off
12:43pm, Thursday, 12'th Feb 2026
Organon reported disappointing 2025 results, with revenues down 3% and no growth expected in 2026. OGN faces potentially terminal declines in established brands, flat biosimilar growth, and underwhelm
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
11:30am, Thursday, 12'th Feb 2026
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Stree
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
10:44am, Thursday, 12'th Feb 2026
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Organon (OGN) Misses Q4 Earnings and Revenue Estimates
09:50am, Thursday, 12'th Feb 2026
Organon (OGN) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.9 per share a year ago.
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
07:30am, Thursday, 12'th Feb 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2025 and Full Year 2025 earnings results, ending December 31, 2025.
Brokerages Set Organon & Co. (NYSE:OGN) Target Price at $8.38
01:32am, Sunday, 08'th Feb 2026
Shares of Organon and Co. (NYSE: OGN - Get Free Report) have been given an average rating of "Reduce" by the seven brokerages that are covering the stock, Marketbeat.com reports. Five investment analy
